Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims
This article was originally published in Pharmaceutical Approvals Monthly
Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.
You may also be interested in...
Berlex’ Leukine is expected to enter Phase III development for moderately to severely active Crohn’s disease in early 2004, but the primary endpoint to be used is still being negotiated with FDA, the Schering AG subsidiary said Oct. 14.
The need for additional studies for Biogen/Elan’s Antegren in Crohn’s disease could hinge upon FDA’s acceptance of data from secondary endpoints or subgroup analysis of the ENACT-1 pivotal trial.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011